Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
184
resultados
Última actualización
21/06/2025 [08:13:00]
Resultados 150 a 175 de 184
Resumen de: US2025134910A1
The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.
Resumen de: WO2025086933A1
The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.
Resumen de: US2025134924A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Resumen de: WO2025090967A1
Provided herein are compositions and methods for treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm with a molecule of formula: and one or more pharmaceutical acceptable excipients or salts; and methods for preventing and/or treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm triggered by a coronavirus 2 (SARS-CoV-2) infection or fibrosis in a subject.
Resumen de: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: EP4545971A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: EP4545970A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: KR20250058640A
본 발명은 세포 표면 가수분해효소를 이용하여 SARS-CoV-2 스파이크 단백질의 에피토프를 유산균의 세포 표면에 고정시키는 방법에 관한 것으로, 본 발명의 락티플랜티바실러스 플란타룸 균주 유래의 세포 표면 가수분해효소는 앵커 모티프를 가지고 있지 않음에도 불구하고, 사람에게 유익하고 안전성이 입증된 유산균의 세포 표면에 목적단백질을 고정시키는 효과가 우수하다. 따라서, 본 발명의 방법을 이용하면 백신용 항원을 간단하고 안전하게 생산할 수 있으므로, 생물공학, 치료용 단백질 의약품, 백신 등 다양한 분야에서 활용될 수 있을 것이다.
Resumen de: EP4545969A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: EP4545559A2
The present invention is part of the field of genetic engineering, more specifically, in the field of production of anti-sars-cov-2 human monoclonal antibodies. The neutralizing human antibodies of the present application can be used in the therapy of COVID19, avoiding hospitalization and aggravation of infected people with a predisposition to develop severe disease. Persons who are not infected but at risk (health and safety professionals, and others) may benefit from preventive treatment. The present invention also relates to a pharmaceutical composition comprising anti-SARS-COV-2 human monoclonal antibodies, as well as a diagnostic kit and use thereof.
Resumen de: AU2023286504A1
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Resumen de: ZA202311432B
The present invention relates to a mutated SARS-CoV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.
Resumen de: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: WO2025083216A1
The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.
Resumen de: WO2025085665A1
A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Resumen de: WO2025084921A1
The present invention relates to the development of formulations based on the glycyrrhizic acid compound due to its antiviral, anti-inflammatory and immunomodulatory properties, as a syrup at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, as a solution for nebulising at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, and as a spray of liposomal nanoparticles at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound. Cough suppressants, bronchospasm inhibitors and anti-corticoids are added, and lastly, the pH is adjusted in a range of 4 - 7 as this is the most physiological range. The invention is for the therapeutic and prophylactic management of infections and clinical symptoms of the infection due to SARS-CoV2 and COVID-19.
Resumen de: US2025130231A1
The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.
Resumen de: US2025130230A1
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
Resumen de: US2025130227A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: US2025127744A1
The present invention relates to treating SARS-CoV-2 infection by concurrent administration of different treatment supplementation through anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The lower doses of the proposed treatment modalities in the present invention denoted anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The higher doses of the proposed treatment modalities in the present invention promoted the release the CD4+ and CD8+ T cell, increasing the phagocytosis activity for viral clearance of SARS-CoV-2 infection. The proposed treatment modalities in the present invention allow the maturation of antibodies against natural SARS-CoV-2 infection.
Resumen de: AU2023356620A1
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: US2025129368A1
The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-COV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5′ terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-COV-2.
Resumen de: US2025129438A1
A method of detecting SARS-CoV includes amplifying isothermally a target sequence in a sample with at least one set of oligonucleotide primers and assaying the sample with a SARS assay to detect the target sequence of a SARS-CoV nucleic acid sequence. A kit for detecting SARS-CoV in a sample includes a reverse transcriptase, a universal primer set suitable for loop-mediated isothermal amplification (LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof containing mutations within one or more primer binding sites.
Nº publicación: US2025127890A1 24/04/2025
Solicitante:
THE BOARD OF REGENTS OF THE UNIV OF OKLAHOMA [US]
THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
Resumen de: US2025127890A1
Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.
BOPI
Sede Electrónica
